We are live on
!
Find out more
B
Braidwell Portfolio holdings
AUM
$2.7B
1-Year Est. Return
88.53%
This Fund
S&P 500
This Quarter
Est. Return
+4.56%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.72B
AUM Growth
-$442M
(-14%)
Cap. Flow
-$1.85B
Cap. Flow
% of AUM
-67.9%
Top 10 Holdings %
Top 10 Hldgs %
40.29%
Holding
91
New
5
Increased
13
Reduced
23
Closed
19
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
argenx
ARGX
|
+$71.4M |
| 2 |
Penumbra
PEN
|
+$28.2M |
| 3 |
TRML
Tourmaline Bio
TRML
|
+$18.1M |
| 4 |
Structure Therapeutics
GPCR
|
+$16.1M |
| 5 |
Lantheus
LNTH
|
+$14M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boston Scientific
BSX
|
+$61.5M |
| 2 |
Natera
NTRA
|
+$44.8M |
| 3 |
MRUS
Merus
MRUS
|
+$35.7M |
| 4 |
Intuitive Surgical
ISRG
|
+$33.6M |
| 5 |
Glaukos
GKOS
|
+$30.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 51.4% |
| 2 | Healthcare | 48.6% |
| 3 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BCYC
51
Bicycle Therapeutics
BCYC
$294M
| – | – |
-1,289,872
| Closed | -$25.9M |
|
|
52
Boston Scientific
BSX
$67.9B
| – | – |
-1,164,850
| Closed | -$61.5M |
|
53
Danaher
DHR
$152B
| – | – |
-87,082
| Closed | -$19.2M |
|
54
Enanta Pharmaceuticals
ENTA
$396M
| – | – |
-1,038,310
| Closed | -$11.6M |
|
|
ETNB
55
DELISTED
89bio
ETNB
| – | – |
-1,590,387
| Closed | -$24.6M |
|
56
Incyte
INCY
$25.2B
| – | – |
-294,900
| Closed | -$17M |
|
57
Ironwood Pharmaceuticals
IRWD
$682M
| – | – |
-1,348,099
| Closed | -$13M |
|
|
58
Intuitive Surgical
ISRG
$132B
| – | – |
-114,920
| Closed | -$33.6M |
|
|
59
Natera
NTRA
$47B
| – | – |
-1,012,145
| Closed | -$44.8M |
|
60
Procept Biorobotics
PRCT
$1.19B
| – | – |
-331,061
| Closed | -$10.9M |
|
61
Protagonist Therapeutics
PTGX
$9.34B
| – | – |
-1,109,150
| Closed | -$18.5M |
|
62
Replimune Group
REPL
$1.46B
| – | – |
-487,520
| Closed | -$8.34M |
|
63
SkinHealth Systems
SKIN
$89.1M
| – | – |
-1,626,236
| Closed | -$9.79M |
|
|
AXNX
64
DELISTED
Axonics, Inc. Common Stock
AXNX
| – | – |
-354,527
| Closed | -$19.9M |
|
|
RYZB
65
DELISTED
RayzeBio, Inc. Common Stock
RYZB
| – | – |
-277,778
| Closed | -$6.17M |
|
|
SGEN
66
DELISTED
Seagen Inc. Common Stock
SGEN
| – | – |
-42,497
| Closed | -$9.02M |
|
Similar funds
CWM
M
AG
NIM
GC
BIAS
CCM
ACP
Braidwell's Q4 2023 Portfolio in Review
As of Q4 2023, Braidwell held 91 positions worth $2.72B, down 14% from $3.16B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Braidwell withdrew a net $1.85B in Q4 2023, closing 19 positions and reducing 23 holdings. Its most notable exit was Boston Scientific, an estimated $61.5M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 51% of assets, up from 48% a quarter earlier, followed by Healthcare and Consumer Staples.
Against the trend, Braidwell opened a new position in argenx worth $58.3M.
- Braidwell's largest Q4 2023 buy was argenx: 153,204 shares worth $58.3M.
- Braidwell added most to Penumbra in Q4 2023, an estimated $28.2M increase.
- Braidwell's biggest Q4 2023 reduction was Merus, cutting an estimated $35.7M.
- Braidwell fully exited Boston Scientific in Q4 2023, selling an estimated $61.5M.
- Braidwell's ten largest holdings make up 40% of its $2.72B portfolio in Q4 2023.
- Braidwell opened 5 new positions and closed 19 in Q4 2023.
- Braidwell's portfolio value fell 14% quarter-over-quarter to $2.72B.
Based on Braidwell's 13F filing for Q4 2023, filed 14 Feb 2024.